U.S. markets close in 3 hours 18 minutes
  • S&P 500

    3,790.77
    +22.30 (+0.59%)
     
  • Dow 30

    31,134.05
    +209.91 (+0.68%)
     
  • Nasdaq

    12,718.87
    -4.60 (-0.04%)
     
  • Russell 2000

    2,138.39
    -8.54 (-0.40%)
     
  • Crude Oil

    65.97
    +2.14 (+3.35%)
     
  • Gold

    1,699.10
    -1.60 (-0.09%)
     
  • Silver

    25.15
    -0.31 (-1.22%)
     
  • EUR/USD

    1.1910
    -0.0068 (-0.57%)
     
  • 10-Yr Bond

    1.5610
    +0.0110 (+0.71%)
     
  • GBP/USD

    1.3816
    -0.0078 (-0.56%)
     
  • USD/JPY

    108.2950
    +0.3190 (+0.30%)
     
  • BTC-USD

    47,926.34
    -1,902.77 (-3.82%)
     
  • CMC Crypto 200

    958.86
    +15.69 (+1.66%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BIIB, BRY and NERV

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Biogen Inc. (NASDAQ:BIIB)

Investors Affected : October 22, 2019 - November 6, 2019

A class action has commenced on behalf of certain shareholders in Biogen Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/biogen-inc-loss-submission-form/?id=11935&from=1

Berry Corporation (NASDAQ:BRY)

Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company's initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusive

A class action has commenced on behalf of certain shareholders in Berry Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry's operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company's productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company's revenues; and (iv) as a result, the Offering Documents and the Company's public statements were materially false and/or misleading and failed to state information required to be stated therein.

Shareholders may find more information at https://securitiesclasslaw.com/securities/berry-corporation-loss-submission-form/?id=11935&from=1

Minerva Neurosciences, Inc. (NASDAQ:NERV)

Investors Affected : May 15, 2017 - November 30, 2020

A class action has commenced on behalf of certain shareholders in Minerva Neurosciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/minerva-neurosciences-inc-loss-submission-form/?id=11935&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/623116/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-BIIB-BRY-and-NERV